Novo’s booming semaglutide franchise for diabetes and obesity is the standout inclusion in this year’s list. The U.S. Department of Health and Human Services unveiled the list of 15 drugs Friday.

STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 ...

A new study shows that semaglutide can improve glucose levels for people with type 1 diabetes who use automated pumps, without increasing hypoglycemia. In this double-blinded randomized trial ...